Skip to main content
Top
Published in: Respiratory Research 1/2021

Open Access 01-12-2021 | Ritonavir | Research

More skilled clinical management of COVID-19 patients modified mortality in an intermediate respiratory intensive care unit in Italy

Published in: Respiratory Research | Issue 1/2021

Login to get access

Abstract

Background

Some studies investigated epidemiological and clinical features of laboratory-confirmed patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) the virus causing coronavirus disease 2019 (COVID-19), but limited attention has been paid to the follow-up of hospitalized patients on the basis of clinical setting and the expertise of clinical management.

Methods

In the present single-centered, retrospective, observational study, we reported findings from 87 consecutive laboratory-confirmed COVID-19 patients with moderate-to-severe acute respiratory syndrome hospitalized in an intermediate Respiratory Intensive Care Unit (RICU), subdividing the patients in two groups according to the admission date (before and after March 29, 2020).

Results

With improved skills in the clinical management of COVID-19, we observed a significant lower mortality in the T2 group compared with the T1 group and a significantly difference in terms of mortality among the patients transferred in Intensive Care Unit (ICU) from our intermediate RICU (100% in T1 group vs. 33.3% in T2 group). The average length of stay in intermediate RICU of ICU-transferred patients who survived in T1 and T2 was significantly longer than those who died (who died 3.3 ± 2.8 days vs. who survived 6.4 ± 3.3 days). T

Conclusions

The present findings suggested that an intermediate level of hospital care may have the potential to modify survival in COVID-19 patients, particularly in the present phase of a more skilled clinical management of the pandemic.
Literature
6.
go back to reference Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020;8:475–81.CrossRef Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020;8:475–81.CrossRef
7.
go back to reference Phua J, Weng L, Ling L, et al. Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations. Lancet Respir Med. 2020;8:506–17.CrossRef Phua J, Weng L, Ling L, et al. Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations. Lancet Respir Med. 2020;8:506–17.CrossRef
8.
go back to reference Grasselli G, Zangrillo A, Zanella A, et al. Baseline characteristics and outcomes of 1591 patients infected with SARS-Cov-2 admitted to ICUs of the Lombardy Region, Italy. JAMA. 2020;323:1574–81.CrossRef Grasselli G, Zangrillo A, Zanella A, et al. Baseline characteristics and outcomes of 1591 patients infected with SARS-Cov-2 admitted to ICUs of the Lombardy Region, Italy. JAMA. 2020;323:1574–81.CrossRef
9.
go back to reference Siddiqi HK, Mehra MR. COVID-19 illness in native and immunosuppressed states: a clinical-therapeutic staging proposal. J Heart Lung Transplant. 2020;39:405–7.CrossRef Siddiqi HK, Mehra MR. COVID-19 illness in native and immunosuppressed states: a clinical-therapeutic staging proposal. J Heart Lung Transplant. 2020;39:405–7.CrossRef
10.
go back to reference Bone RC, Balk RA. Noninvasive respiratory care unit. A cost effective solution for the future. Chest. 1988;93:390–4.CrossRef Bone RC, Balk RA. Noninvasive respiratory care unit. A cost effective solution for the future. Chest. 1988;93:390–4.CrossRef
12.
go back to reference Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2019;323(2020):1061–9. Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2019;323(2020):1061–9.
13.
go back to reference ARDS Definition Task Force, Ranieri VM, Rubenfeld GD, Thompson BT, et al. Acute respiratory distress syndrome: the Berlin definition. JAMA. 2012; 307:2526–2533. ARDS Definition Task Force, Ranieri VM, Rubenfeld GD, Thompson BT, et al. Acute respiratory distress syndrome: the Berlin definition. JAMA. 2012; 307:2526–2533.
14.
go back to reference Rochwerg B, Brochard L, Elliott MW, et al. Official ERS/ATS clinical practice guidelines: noninvasive ventilation for acute respiratory failure. Eur Respir J. 2017;50:1602426.CrossRef Rochwerg B, Brochard L, Elliott MW, et al. Official ERS/ATS clinical practice guidelines: noninvasive ventilation for acute respiratory failure. Eur Respir J. 2017;50:1602426.CrossRef
15.
go back to reference Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost. 2019;18(2020):1094–9. Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost. 2019;18(2020):1094–9.
16.
go back to reference Cao B, Wang Y, Wen D, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N Engl J Med. 2020;382:1787–99.CrossRef Cao B, Wang Y, Wen D, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N Engl J Med. 2020;382:1787–99.CrossRef
17.
go back to reference Cain DW, Cidlowski JA. After 62 years of regulating immunity, dexamethasone meets COVID-19. Nat Rev Immunol. 2020;20:587–8.CrossRef Cain DW, Cidlowski JA. After 62 years of regulating immunity, dexamethasone meets COVID-19. Nat Rev Immunol. 2020;20:587–8.CrossRef
18.
go back to reference Yao X, Ye F, Zhang M, et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis. 2020;71:732–9.CrossRef Yao X, Ye F, Zhang M, et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis. 2020;71:732–9.CrossRef
19.
go back to reference Hong KS, Lee KH, Chung JH, et al. Clinical features and outcomes and outcomes of 98 patients hospitalized with SARS-COVID19 infection in Daegu, South Korea: a brief descriptive study. Yonsei Med J. 2020;61:431–7.CrossRef Hong KS, Lee KH, Chung JH, et al. Clinical features and outcomes and outcomes of 98 patients hospitalized with SARS-COVID19 infection in Daegu, South Korea: a brief descriptive study. Yonsei Med J. 2020;61:431–7.CrossRef
20.
go back to reference Piva S, Filippini M, Turla F, et al. Clinical presentation and initial management critically ill patients with severe acute respiratory distress syndrome coronavirus (SarsCov2) infection in Brescia, Italy. J Crit Care. 2020;58:29–33.CrossRef Piva S, Filippini M, Turla F, et al. Clinical presentation and initial management critically ill patients with severe acute respiratory distress syndrome coronavirus (SarsCov2) infection in Brescia, Italy. J Crit Care. 2020;58:29–33.CrossRef
21.
go back to reference Zhang JJY, Lee KS, Ang LW, et al. Risk factors of severe disease and efficacy of treatment in patients infected with COVID-19: a systematic review, meta-analysis and meta-regression analysis. Clin Infect Dis. 2020;71:2199–206.CrossRef Zhang JJY, Lee KS, Ang LW, et al. Risk factors of severe disease and efficacy of treatment in patients infected with COVID-19: a systematic review, meta-analysis and meta-regression analysis. Clin Infect Dis. 2020;71:2199–206.CrossRef
23.
go back to reference Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30:269–71.CrossRef Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30:269–71.CrossRef
24.
go back to reference Ayele Mega T, Feyissa TM, Dessalegn Bosho D, et al. The outcome of hydroxychloroquine in patients treated for COVID-19: systematic review and meta-analysis. Can Respir J. 2020;13:4312519. Ayele Mega T, Feyissa TM, Dessalegn Bosho D, et al. The outcome of hydroxychloroquine in patients treated for COVID-19: systematic review and meta-analysis. Can Respir J. 2020;13:4312519.
25.
go back to reference Kannan R, Przekwas A. A multiscale absorption and transit model for oral delivery of hydroxychloroquine: pharmacokinetic modeling and intestinal concentration prediction to assess toxicity and drug-induced damage in healthy subjects. Int J Numer Method Biomed Eng. 2020;36:e3403.PubMed Kannan R, Przekwas A. A multiscale absorption and transit model for oral delivery of hydroxychloroquine: pharmacokinetic modeling and intestinal concentration prediction to assess toxicity and drug-induced damage in healthy subjects. Int J Numer Method Biomed Eng. 2020;36:e3403.PubMed
26.
go back to reference Kannan R, Singh N, Przekwas A. A Quasi-3D compartmental multi-scale approach to detect and quantify diseased regional lung constriction using spirometry data. Int J Numer Method Biomed Eng. 2018;34:e2973.CrossRef Kannan R, Singh N, Przekwas A. A Quasi-3D compartmental multi-scale approach to detect and quantify diseased regional lung constriction using spirometry data. Int J Numer Method Biomed Eng. 2018;34:e2973.CrossRef
Metadata
Title
More skilled clinical management of COVID-19 patients modified mortality in an intermediate respiratory intensive care unit in Italy
Publication date
01-12-2021
Published in
Respiratory Research / Issue 1/2021
Electronic ISSN: 1465-993X
DOI
https://doi.org/10.1186/s12931-021-01613-2

Other articles of this Issue 1/2021

Respiratory Research 1/2021 Go to the issue